Ipamorelin vs CJC-1295
The commonly paired GH secretagogue and GHRH analogue.
Ipamorelin Acetate
A selective growth hormone secretagogue and ghrelin receptor agonist that stimulates pulsatile GH release with minimal effect on cortisol or prolactin.
CJC-1295 (GHRH analogue)
A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.
| Attribute | Ipamorelin | CJC-1295 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Not FDA-approved | Not FDA-approved |
| Half-life | ~2 hours | ~6-8 days (DAC version) |
| Molecular weight | 711.85 Da | 3,647.2 Da |
| Mechanism | Agonizes the ghrelin/GH secretagogue receptor (GHS-R1a) on the pituitary, stimulating pulsatile growth hormone secretion. | Activates the GHRH receptor on the pituitary to increase growth hormone secretion; albumin binding prolongs its activity. |
| Legal status (US) | Not approved; research use only | Not approved; research use only |
Frequently asked questions
What is the difference between Ipamorelin and CJC-1295?
Ipamorelin: A selective growth hormone secretagogue and ghrelin receptor agonist that stimulates pulsatile GH release with minimal effect on cortisol or prolactin. CJC-1295: A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.
Which has stronger research evidence, Ipamorelin or CJC-1295?
Ipamorelin is rated Moderate and CJC-1295 is rated Moderate for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Ipamorelin and CJC-1295 FDA-approved?
Ipamorelin: Not FDA-approved. CJC-1295: Not FDA-approved.
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.